kyron.bio
Kyron.bio develops a glycan-engineering platform designed to modify glycosylation patterns on protein therapeutics. The technology aims to improve the efficacy of antibody therapeutics and transform patient outcomes. The company focuses on preclinical studies and R&D to deliver modified therapeutic drugs for the healthcare sector.
Visit websiteParis, France
Healthtech
Biotechnology
Therapeutics
Funding summary
- Total raised
- €5.5M
- Funding rounds
- 1
Investors in kyron.bio
Investors on record for kyron.bio. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like kyron.bio?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors